Industries > Pharma > Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031
Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031
Forecasts by Product (Lucentis, Eylea, Avastin, Visudyne, Others), by Indication (AMD, Diabetic, Macular, Edema, Diabetic, Retinopathy, Retinal Vein, Occlusion, Others), by End-User (Hospital Pharmacy, Retail, Pharmacy, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios
The global AMD and other retinal disease drugs market accounted for US$xx billion in 2020 and is expected to grow at a CAGR of xx% during the forecast period to reach US$xx billion by 2031. Growing investment in drug R&D by pharmaceutical and biopharmaceutical companies, rising prevalence of retinal diseases, mounting demand for biologics & biosimilars, and developing healthcare infrastructure in emerging economies are some of the major factors that propel the market growth.
Age-related macular degeneration accounts for 8.7% of all blindness worldwide and is the most common cause of blindness in developed countries particularly in people older than 60 years. The prevalence of AMD is likely to increase as a consequence of exponential population ageing.
There have been significant advances in the management of wet age-related macular degeneration with the introduction of anti-angiogenesis therapy, and patients now have effective treatment options that can prevent blindness and, in many cases, restore vision. However, these treatments are expensive and not available to all patients in many countries. The report explains that growth in the market will be driven by the entry of longer-acting anti-angiogenic therapies and the launch of products for dry AMD and geographic atrophy (GA), which are two forms of advanced disease for which there are no approved therapies. Thus, understanding the burden, population impact and treatments options is essential to develop strategies for adequate health care planning and delivery, which require both precise and modern market estimates.
How this report will benefit you
The report provides a thoughtful understanding into the global age-related macular degeneration market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, PEST analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the macular degeneration industry in any manner.
As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
To access the data contained in this document please email contactus@visiongain.com
In this brand-new 445-page report you will receive 279 charts– all unavailable elsewhere.
The 445-page Visiongain report provides clear detailed insight into the macular degeneration market. Discover the key trends and development in the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global macular degeneration and other retinal diseases drug market forecasts from 2021-2031
• This report also breaks down the revenue forecast to 2031 for the global macular degeneration and other retinal diseases drug market by indication, type, product and distribution channel:
• By Indication
– Diabetic Macular Edema
– Diabetic Retinopathy
– Retinal Vein Occlusion
– Others
• By Type
– Wet AMD
– Dry AMD
– Geographic Atrophy
• By Product
– Lucentis
– Eylea
– Avastin
– Visudyne
– Others
• By Distribution Channel
– Hospital Pharmacy
– Retail Pharmacy
– Others
This report discusses the market trends and developments of each submarket.
Need industry data? Please contact us today.
• Our study discusses the selected leading companies that are the major players in the macular degeneration (AMD) and other retinal diseases drugs market:
– Novartis AG
– F. Hoffmann-La Roche, Ltd.
– GlaxoSmithKline Pharmaceuticals Ltd.
– Bayer AG
– Pfizer Inc.
– Regeneron Pharmaceuticals
– Bausch & Lomb Incorporated
– Apellis Pharmaceuticals
– Santen Pharmaceuticals
– Alimera Sciences
– AbbVie Inc.
– IVERIC bio, Inc. (Formerly Ophthotech)
– Graybug Vision, Inc.
– Kubota Vision Inc.
Visiongain’s study is intended for anyone requiring commercial analyses for the global macular degeneration (AMD) and other retinal diseases drugs market. You find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031: Forecasts by Product (Lucentis, Eylea, Avastin, Visudyne, Others), by Indication (AMD, Diabetic, Macular, Edema, Diabetic, Retinopathy, Retinal Vein, Occlusion, Others), by End-User (Hospital Pharmacy, Retail, Pharmacy, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1 Introduction to Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market
1.1.1 What are Retinal Diseases?
1.1.2 Types of Retinal Diseases
1.1.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
1.1.4 Nearly 200 Million People with AMD?
1.1.5 Over 100 Million with DR
1.1.6 First RVO Estimates Suggest Patient Population of 16 Million
1.2 Why You Should Read This Report
1.3 What This Report Delivers
1.4 Key Questions Answered By This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation & Forecast Methodology
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2 Executive Summary
3 Market Dynamics
3.1 Drivers
3.1.1 Rise in Incidence of Retinal Disorders
3.1.2 Upsurge in Geriatric Population
3.2 Restraints
3.2.1 Increasing Use of Generic Drugs
3.2.2 Lack of Awareness regarding AMD
3.2.3 Stringent FDA Regulations
3.3 Opportunities
3.3.1 Growing Demand for Cutting-edge Therapeutic Treatments for Retinal Diseases to Aid Market
3.3.2 Untapped Opportunities for the Dry-AMD Treatment
3.4 Trends
3.4.1 Mergers, Agreements, and Acquisitions By The Market Players
3.4.2 New Product Launches to Drive Market
3.5 SWOT Analysis
3.5.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
3.5.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
3.5.3 Opportunities: New Markets and R&D Synergies
3.5.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
3.6 Porter’s Five Forces Analysis
3.6.1 Bargaining Power of Supplier: Moderate
3.6.2 Bargaining Power of Buyer: Moderate
3.6.3 Competitive Rivalry: High
3.6.4 Threat of New Entrants: Moderate
3.6.5 Threat of Substitutes: Moderate
3.7 PEST Analysis
3.7.1 Political Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: The Demography and Diabetes Challenges
3.7.2 Economic Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: Off-Label Treatment and Reimbursement Issues
3.7.3 Social Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: Low Diagnosis, Low Compliance
3.7.4 Technological Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: Innovation for the Eye
4 COVID-19 Impact: Global AMD and Other Disease Drugs Market
4.1.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
4.1.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
4.1.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
4.1.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth
5 World AMD and Other Disease Drugs Market, 2020
5.1 Market to Grow Rapidly by 2031
5.2 Eylea Became Leading Drug in the Market
5.3 Regeneron is the Leading Player in the Retinal Drug Market
6 AMD and Other Disease Drugs Market by Indication Forecast, 2021-2031
6.1 AMD Segment Market Forecast, 2021-2031
6.1.1 Largest Revenue-Grossing Segment
6.1.2 Recovery Scenarios (V, U, W, L)
6.1.3 Wet AMD Segment Market Forecast, 2021-2031
6.1.3.1 Wet AMD Angiogenic Processes Offer Well-Defined Drug Targets
6.1.3.2 Wet AMD Segment Market Forecast, 2021-2031
6.1.3.3 Recovery Scenarios (V, U, W, L)
6.1.4 Dry AMD Segment Market Forecast, 2021-2031
6.1.4.1 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
6.1.4.2 Revenue Forecast for Wet AMD segment, 2020-2031
6.1.4.3 Recovery Scenarios (V, U, W, L)
6.1.5 Geographic Atrophy Segment Market Forecast, 2021-2031
6.1.5.1 Geographic Atrophy: Unmet Need to Arrest or Reverse Damage to RPE
6.1.5.2 Revenue Forecast for Geographic Atrophy segment, 2020-2031
6.1.5.3 Recovery Scenarios (V, U, W, L)
6.2 Diabetic Macular Edema Market Forecast, 2021-2031
6.2.1 Fast Growing Segment
6.2.2 Revenue Forecast for Diabetic Macular Edema segment, 2020-2031
6.2.3 Recovery Scenarios (V, U, W, L)
6.3 Diabetic Retinopathy Market Forecast, 2021-2031
6.3.1 Diabetic Retinopathy: Coming into Clinical Focus, with DME the Main Target
6.3.2 Segment to Grow in Importance as Diabetes Epidemic Continues
6.3.3 Recovery Scenarios (V, U, W, L)
6.4 Retinal Vein Occlusion Market Forecast, 2021-2031
6.4.1 Retinal Vein Occlusion Is The Second Most Common Vascular Disease Of The Retina
6.4.2 Recovery Scenarios (V, U, W, L)
6.5 Other Retinal Diseases Market Forecast, 2021-2031
6.5.1 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
6.5.2 Recovery Scenarios (V, U, W, L)
7 AMD and Other Disease Drugs Market by Product Forecast, 2021-2031
7.1 Will the Current Products Dominate the Market through 2031?
7.2 Lucentis: Second Leading Drug in the Market
7.2.1 Recovery Scenarios (V, U, W, L)
7.2.2 Shadow of Avastin Still Hangs Over Lucentis
7.2.3 Lucentis/Avastin Matters
7.2.4 Eylea: The Bigger Threat to Lucentis?
7.2.5 Extending the Label, Widening the Battleground: Lucentis Moves into DME and Beyond
7.2.6 Improving Cost and Compliance for Lucentis
7.2.7 Will Loss of Physician Goodwill Harm Lucentis' Growth?
7.3 Eylea: Holds the Throne?
7.3.1 Increasing Revenue Growth in Past: Outside the US Sale Amplified
7.3.2 Recovery Scenarios (V, U, W, L)
7.3.3 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
7.3.4 First Wave of Eylea's Expansion Finally Beginning to Break?
7.3.5 Eylea into DME and Other New Indications
7.3.6 How Far Can Eylea's Momentum Carry It?
7.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
7.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
7.4.2 Recovery Scenarios (V, U, W, L)
7.4.3 Judicial Review Averted in the UK by Price Adjustment
7.4.4 Multiple Attempts to Block Off-Label Avastin Since 2007
7.4.5 Roche and Novartis Challenge CATTs Headline Conclusions
7.4.6 Will Eylea/Zaltrap Affect Avastin's Place in the Market?
7.4.7 Will Anything Dislodge Avastin from its Central Position?
7.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
7.5.1 Visudyne Revenue Forecast, 2021-2031
7.5.2 Recovery Scenarios (V, U, W, L)
7.6 Other Drugs for Macular Degeneration and Other Retinal Diseases
7.6.1 Other Drugs Revenue Forecast, 2021-2031
7.6.2 Recovery Scenarios (V, U, W, L)
8 Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Distribution Channel Forecast, 2021-2031
8.1 Hospital Pharmacy Segment Market Forecast, 2021-2031
8.1.1 Largest Revenue Generating Segment
8.1.2 Recovery Scenarios (V, U, W, L)
8.2 Retail Pharmacy Segment Market Forecast, 2021-2031
8.2.1 Fastest Growing Segment in the Market
8.2.2 Recovery Scenarios (V, U, W, L)
8.3 Others Segment Market Forecast, 2021-2031
8.3.1 Developing Healthcare Infrastructure Is Expected To Drive The Market Growth
8.3.2 Recovery Scenarios (V, U, W, L)
9 Wet AMD Segment: Pipeline Analysis
9.1 The Leading Pipeline Candidates
9.2 Eylea® (aflibercept)
9.3 Brolucizumab (Novartis)
9.4 KSI-301
9.5 OPT-302
9.6 GB-102
9.7 Combination of Drugs for the Treatment of AMD and Other Retinal Diseases
9.7.1 Anti-VEGF and Cosopt (Dorzolamide-timolol) Drugs
9.7.2 REGN 910-3 and RG7716
9.7.3 Anti-VEGF and OPT-302 Drugs
9.7.4 Others Combination Therapy Developments
10 Pipeline for Dry AMD Segment
10.1 Apl-2
10.2 Zimura
10.3 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
10.4 Neuroprotection: One of Modern Medicine's Holy Grails
10.5 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
10.6 Elamipretide
10.7 Subthreshold Nanosecond Laser
10.8 Lampalizumab
11 Pipeline for Diabetic Retinopathy Segment
11.1 Steroids in Development for DR
11.2 APX3330
12 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
12.1 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Region Forecast 2021-2031
12.2 Recovery Scenarios (V, U, W, L)
12.3 Epidemiology of Global Age-Related Macular Degeneration in Nine Major Pharmaceutical Markets
13 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
13.1 North America is The Largest Revenue Grossing Region in the Global Market
13.2 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
13.3 Recovery Scenarios (V, U, W, L)
13.4 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
13.5 North America Macular Degeneration (AMD) Drugs Market Forecast by Type
13.6 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
13.7 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
13.8 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
13.8.1 Rise In The Number Of Drug Approvals
13.8.2 Presence of Highly Developed Healthcare Infrastructure
13.8.3 Recovery Scenarios (V, U, W, L): U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
13.9 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
13.9.1 Anticipated To Witness The Fastest Growth In The North America Region
13.9.2 Benefits Of Manufacturing And R&D Operations In Canada
13.9.3 Recovery Scenarios (V, U, W, L): Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
14.1 Second Largest Market in the Global Market
14.2 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
14.3 Recovery Scenarios (V, U, W, L)
14.4 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
14.5 Europe Macular Degeneration (AMD) Drugs Market Forecast by Type
14.6 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
14.7 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
14.8 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.8.1 Growing Geriatric Population In This Region Is Expected To Boost The Regional Market Growth
14.8.2 One Of The Oldest Universal Health Systems Within Europe
14.8.3 Recovery Scenarios (V, U, W, L): Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.9 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.9.1 Presence Of Well-Developed R&D Infrastructure
14.9.2 Increasing Prevalence Of Retinal Diseases In This Region
14.9.3 Recovery Scenarios (V, U, W, L): UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.10 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.10.1 Growing Demand For Affordable Healthcare Services
14.10.2 Growing Demand For Innovative Medicine And Pharmaceutical
14.10.3 Recovery Scenarios (V, U, W, L): France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.11 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.11.1 Pharmaceutical Manufacturing Hub
14.11.2 Growing Demand For Advanced Therapies For The Treatment Of Retinal Diseases
14.11.3 Recovery Scenarios (V, U, W, L): Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.12 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.12.1 Spanish Economy Is Growing Strong
14.12.2 Demand For Drugs Is Influenced By The Growth Of The Pharmaceutical Industry
14.12.3 Recovery Scenarios (V, U, W, L): Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.13 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.13.1 Unmet Pharmaceutical Needs
14.13.2 Government Support For Development of the Healthcare Infrastructure
14.13.3 Recovery Scenarios (V, U, W, L): Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.14 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.14.1 Increasing Prevalence Of Retinal Diseases
14.14.2 Recovery Scenarios (V, U, W, L): Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
15.1 Asia Pacific is the Fastest Growing Market
15.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
15.3 Recovery Scenarios (V, U, W, L)
15.4 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
15.5 Asia Pacific Macular Degeneration (AMD) Drugs Market Forecast by Type
15.6 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
15.7 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
15.8 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.8.1 Japan Accounted For The Largest Market Share In The Asia Pacific Region
15.8.2 Japan Spent A High Amount On Healthcare
15.8.3 Recovery Scenarios (V, U, W, L): Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.9 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.9.1 Presence Of Large Geriatric Population
15.9.2 Increasing Healthcare Spending In China
15.9.3 Recovery Scenarios (V, U, W, L): China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.10 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.10.1 Developing Healthcare Infrastructure
15.10.2 Increasing Prevalence Of Retinal Diseases
15.10.3 Recovery Scenarios (V, U, W, L): India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.11 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.11.1 Government Programs To Expand Access To Quality Eye Care Facilities
15.11.2 Well Established Healthcare Infrastructure
15.11.3 Recovery Scenarios (V, U, W, L): Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.12 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.12.1 Growing Healthcare Awareness Among People
15.12.2 Increasing Prevalence Of Retinal Diseases
15.12.3 Recovery Scenarios (V, U, W, L): South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.13 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.13.1 Rising Disposable Income
15.13.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
16.1 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market
16.2 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
16.3 Recovery Scenarios (V, U, W, L)
16.4 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
16.5 Latin America Macular Degeneration (AMD) Drugs Market Forecast by Type
16.6 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
16.7 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
16.8 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.8.1 Fastest Growing Economies in Latin America
16.8.2 Government Incentives to Keep Manufacturing Local
16.8.3 Recovery Scenarios (V, U, W, L): Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.9 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.9.1 Lower Manufacturing Costs Than In The US
16.9.2 R&D And Drug Approval Process in Mexico Has Several Advantages
16.9.3 Recovery Scenarios (V, U, W, L): Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.10 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.10.1 Boom in Pharmaceutical Industry
16.10.2 Adoption Of AMD And Other Retinal Diseases Drugs For The Treatment Of Retinal Diseases
16.10.3 Recovery Scenarios (V, U, W, L): Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.11 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.11.1 Developing Healthcare Infrastructure
16.11.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
17.1 Rising Prevalence of Chronic Retinal Diseases
17.2 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
17.3 Recovery Scenarios (V, U, W, L)
17.4 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
17.5 MEA Macular Degeneration (AMD) Drugs Market Forecast by Type
17.6 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
17.7 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
17.8 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.8.1 Increasing Focus Of Pharmaceutical & Pharmaceutical Companies In This Region
17.8.2 Supportive Government Initiatives
17.8.3 Recovery Scenarios (V, U, W, L): South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.9 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.9.1 Presence Of Huge Growth Opportunities
17.9.2 Rising Prevalence Of The Diseases
17.9.3 Recovery Scenarios (V, U, W, L): Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.10 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.10.1 Strong Presence Of Leading Companies
17.10.2 Growing Prevalence of Retinal Diseases
17.10.3 Recovery Scenarios (V, U, W, L): Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
18 Company Profiles
18.1 Company Share Analysis
18.2 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Recent Developments, 2017-2020
18.3 Novartis AG
18.3.1 Company Snapshot
18.3.2 Company Overview
18.3.3 Financial Analysis
18.3.3.1 Net Revenue, 2015-2019
18.3.3.2 Product Revenue Shares, 2019
18.3.3.3 Novartis Pharmaceuticals Business Unit Revenue Shares, 2019
18.3.3.4 Regional Revenue Shares, 2019
18.3.4 Product Benchmarking
18.3.5 Recent Developments, 2017-2020
18.4 F. Hoffmann-La Roche, Ltd.
18.4.1 Company Snapshot
18.4.2 Company Overview
18.4.3 Financial Analysis
18.4.3.1 Net Revenue, 2015-2019
18.4.3.2 Product Revenue Shares, 2019
18.4.3.3 Pharmaceuticals Business Revenue Shares, 2019
18.4.3.4 Regional Revenue Shares, 2019
18.4.4 Product Benchmarking
18.4.5 Recent Developments, 2017-2020
18.5 GlaxoSmithKline Pharmaceuticals Ltd.
18.5.1 Company Snapshot
18.5.2 Company Overview
18.5.3 Financial Analysis
18.5.3.1 Net Revenue, 2015-2019
18.5.3.2 Product Revenue Shares, 2019
18.5.3.3 Pharmaceuticals Segment Revenue Shares, 2019
18.5.3.4 Regional Revenue Shares, 2019
18.5.4 Product Benchmarking
18.5.5 Recent Developments, 2017-2020
18.6 Bayer AG
18.6.1 Company Snapshot
18.6.2 Company Overview
18.6.3 Financial Analysis
18.6.3.1 Net Revenue, 2015-2019
18.6.3.2 Product Revenue Shares, 2019
18.6.3.3 Regional Revenue Shares, 2019
18.6.4 Product Benchmarking
18.6.5 Recent Developments, 2017-2020
18.7 Pfizer Inc.
18.7.1 Company Snapshot
18.7.2 Company Overview
18.7.3 Financial Analysis
18.7.3.1 Net Revenue, 2015-2019
18.7.3.2 Product Revenue Shares, 2019
18.7.3.3 Regional Revenue Shares, 2019
18.7.4 Product Benchmarking
18.7.5 Recent Developments, 2017-2020
18.8 Regeneron Pharmaceuticals
18.8.1 Company Snapshot
18.8.2 Company Overview
18.8.3 Financial Analysis
18.8.3.1 Net Revenue, 2015-2019
18.8.3.2 Product Revenue Shares, 2019
18.8.3.3 Regional Revenue Shares, 2019
18.8.4 Product Benchmarking
18.8.5 Recent Developments, 2017-2020
18.9 Bausch & Lomb Incorporated
18.9.1 Company Snapshot
18.9.2 Company Overview
18.9.3 Financial Analysis
18.9.3.1 Net Revenue, 2015-2019
18.9.3.2 Product Revenue Shares, 2019
18.9.3.3 Regional Revenue Shares, 2019
18.9.4 Product Benchmarking
18.9.5 Recent Developments, 2017-2020
18.10 Apellis Pharmaceuticals
18.10.1 Company Snapshot
18.10.2 Company Overview
18.10.3 Product Benchmarking
18.10.4 Recent Developments, 2017-2020
18.11 Santen Pharmaceuticals
18.11.1 Company Snapshot
18.11.2 Company Overview
18.11.3 Financial Analysis
18.11.3.1 Net Revenue, 2015-2019
18.11.4 Product Benchmarking
18.11.5 Recent Developments, 2017-2020
18.12 Alimera Sciences
18.12.1 Company Snapshot
18.12.2 Company Overview
18.12.3 Financial Analysis
18.12.3.1 Net Revenue, 2015-2019
18.12.3.2 Regional Revenue Shares, 2019
18.12.4 Product Benchmarking
18.12.5 Recent Developments, 2017-2020
18.13 AbbVie Inc.
18.13.1 Company Snapshot
18.13.2 Company Overview
18.13.3 Financial Analysis
18.13.3.1 Net Revenue, 2015-2019
18.13.3.2 Product Revenue Shares, 2019
18.13.3.3 Regional Revenue Shares, 2019
18.13.4 Product Benchmarking
18.13.5 Recent Developments, 2017-2020
18.14 IVERIC bio, Inc. (Formerly Ophthotech)
18.14.1 Company Snapshot
18.14.2 Company Overview
18.14.3 Product Benchmarking
18.15 Graybug Vision, Inc.
18.15.1 Company Snapshot
18.15.2 Company Overview
18.15.3 Product Benchmarking
18.16 Kubota Vision Inc.
18.16.1 Company Snapshot
18.16.2 Company Overview
18.16.3 Product Benchmarking
19 Conclusion and Recommendations
19.1 Increasing Prevalence of Retinal Disorders and Diabetes is a Major Factor Driving The Market Growth
19.2 Negative Impact of the COVID-19 Pandemic on the Market
19.3 Eylea Dominated the AMD and Other Retinal Diseases Market
19.4 Market Opportunities in the Emerging Economies
List of Tables
Table 1 Global AMD and other retinal disease drugs market, 2020 & 2031 (US$ bn, CAGR %)
Table 2 World AMD and Other Retinal Diseases Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "V" Shaped Recovery
Table 3 World AMD and Other Retinal Diseases Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "U" Shaped Recovery
Table 4 World AMD and Other Retinal Diseases Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "W" Shaped Recovery
Table 5 World AMD and Other Retinal Diseases Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "L" Shaped Recovery
Table 6 World AMD and Other Retinal Diseases Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031
Table 7 Market Breakdown by Product: Revenue ($Bn), Market Share (%), 2020 (Pre COVID)
Table 8 Global AMD and Other Disease Drugs Market Forecast by Indication: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 9 Global Retinal Diseases Market Forecasts by Indication: Revenue: ($bn), Market Share (%) for 2021, 2026 and 2031
Table 10 Global AMD and Other Disease Drugs Market for AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 11 Global AMD and Other Disease Drugs Market for AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 12 Global AMD and Other Disease Drugs Market for AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 13 Global AMD and Other Disease Drugs Market for AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 14 Global AMD and Other Disease Drugs Market for AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 15 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2020
Table 16 Global Wet AMD Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 17 Global AMD Market for Wet AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 18 Global AMD Market for Wet AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 19 Global AMD Market for Wet AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 20 Global AMD Market for Wet AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 21 Global AMD Market for Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 22 Global AMD Market for Dry AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 23 Global AMD Market for Dry AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 24 Global AMD Market for Dry AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 25 Global AMD Market for Dry AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 26 Global Geographic Atrophy (GA) Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 27 Global AMD Market for Geographic Atrophy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 28 Global AMD Market for Geographic Atrophy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 29 Global AMD Market for Geographic Atrophy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 30 Global AMD Market for Geographic Atrophy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 31 Global Diabetic Macular Edema Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 32 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 33 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 34 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 35 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 36 Global Diabetic Retinopathy Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 37 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 38 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 39 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 40 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 41 Global Retinal Vein Occlusion Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 42 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 43 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 44 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 45 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 46 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 47 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 48 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 49 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 50 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 51 Global Retinal Diseases Market Forecast by Drugs: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 52 Global Retinal Diseases Market Forecasts by Product: Revenue: ($bn), Market Share (%) for 2021, 2026 and 2031
Table 53 Global Lucentis Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 54 Global AMD and Other Disease Drugs Market for Lucentis Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 55 Global AMD and Other Disease Drugs Market for Lucentis Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 56 Global AMD and Other Disease Drugs Market for Lucentis Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 57 Global AMD and Other Disease Drugs Market for Lucentis Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 58 Lucentis, Eylea and Avastin: Comparison
Table 59 Global Eylea Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 60 Global AMD and Other Disease Drugs Market for Eylea Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 61 Global AMD and Other Disease Drugs Market for Eylea Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 62 Global AMD and Other Disease Drugs Market for Eylea Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 63 Global AMD and Other Disease Drugs Market for Eylea Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 64 Global Avastin Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 65 Global AMD and Other Disease Drugs Market for Avastin Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 66 Global AMD and Other Disease Drugs Market for Avastin Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 67 Global AMD and Other Disease Drugs Market for Avastin Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 68 Global AMD and Other Disease Drugs Market for Avastin Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 69 Global Visudyne Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 70 Global AMD and Other Disease Drugs Market for Visudyne Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 71 Global AMD and Other Disease Drugs Market for Visudyne Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 72 Global AMD and Other Disease Drugs Market for Visudyne Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 73 Global AMD and Other Disease Drugs Market for Visudyne Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 74 Global Other Drugs Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 75 Global AMD and Other Disease Drugs Market for Other Drugs Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 76 Global AMD and Other Disease Drugs Market for Other Drugs Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 77 Global AMD and Other Disease Drugs Market for Other Drugs Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 78 Global AMD and Other Disease Drugs Market for Other Drugs Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 79 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 80 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 81 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 82 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 83 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 84 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 85 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 86 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 87 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 88 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 89 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 90 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 91 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 92 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 93 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 94 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 95 Selected R&D Pipeline for wAMD, 2019
Table 96 Selected R&D Pipeline for Dry AMD, 2019
Table 97 Selected R&D Pipeline for DR, 2019
Table 98 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 99 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 100 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 101 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 102 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 103 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 104 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 105 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 106 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 107 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 108 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 109 North America Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 110 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 111 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 112 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 113 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 114 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 115 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 116 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 117 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 118 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 119 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 120 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 121 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 122 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 123 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 124 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 125 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 126 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 127 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 128 Europe Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 129 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 130 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 131 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 132 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 133 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 134 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 135 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 136 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 137 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 138 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 139 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 140 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 141 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 142 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 143 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 144 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 145 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 146 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 147 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 148 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 149 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 150 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 151 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 152 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 153 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 154 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 155 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 156 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 157 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 158 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 159 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 160 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 161 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 162 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 163 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 164 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 165 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 166 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 167 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 168 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 169 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 170 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 171 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 172 Asia Pacific Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 173 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 174 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 175 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 176 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 177 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 178 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 179 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 180 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 181 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 182 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 183 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 184 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 185 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 186 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 187 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 188 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 189 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 190 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 191 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 192 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 193 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 194 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 195 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 196 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 197 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 198 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 199 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 200 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 201 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 202 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 203 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 204 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 205 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 206 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 207 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 208 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 209 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 210 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 211 Latin America Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 212 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 213 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 214 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 215 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 216 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 217 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 218 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 219 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 220 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 221 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 222 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 223 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 224 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 225 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 226 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 227 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 228 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 229 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 230 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 231 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 232 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 233 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 234 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 235 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 236 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 237 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 238 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 239 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 240 MEA Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 241 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 242 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 243 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 244 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 245 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 246 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 247 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 248 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 249 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 250 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 251 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 252 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 253 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 254 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 255 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 256 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 257 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 258 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Recent Developments, 2017-2020
Table 259 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 260 Novatis AG: Product Benchmarking
Table 261 Novatis AG: Recent Developments, 2017-2020
Table 262 F. Hoffmann-La Roche, Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 263 F. Hoffmann-La Roche, Ltd.: Product Benchmarking
Table 264 F. Hoffmann-La Roche, Ltd.: Recent Developments, 2017-2020
Table 265 GlaxoSmithKline Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 266 GlaxoSmithKline Pharmaceuticals Ltd.: Product Benchmarking
Table 267 GlaxoSmithKline Pharmaceuticals Ltd.: Recent Developments, 2017-2020
Table 268 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 269 Bayer AG: Product Benchmarking
Table 270 Bayer AG: Recent Developments, 2017-2020
Table 271 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 272 Pfizer Inc.: Product Benchmarking
Table 273 Pfizer Inc.: Recent Developments, 2017-2020
Table 274 Regeneron Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 275 Regeneron Pharmaceuticals: Product Benchmarking
Table 276 Regeneron Pharmaceuticals: Recent Developments, 2017-2020
Table 277 Bausch & Lomb Incorporated: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 278 Bausch & Lomb Incorporated: Product Benchmarking
Table 279 Bausch & Lomb Incorporated: Recent Developments, 2017-2020
Table 280 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 281 Apellis Pharmaceuticals: Product Benchmarking
Table 282 Apellis Pharmaceuticals: Recent Developments, 2017-2020
Table 283 Santen Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 284 Santen Pharmaceuticals: Product Benchmarking
Table 285 Santen Pharmaceuticals: Recent Developments, 2017-2020
Table 286 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 287 Alimera Sciences: Product Benchmarking
Table 288 Alimera Sciences: Recent Developments, 2017-2020
Table 289 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 290 AbbVie Inc.: Product Benchmarking
Table 291 AbbVie Inc.: Recent Developments, 2017-2020
Table 292 IVERIC bio, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 293 IVERIC bio, Inc.: Product Benchmarking
Table 294 Graybug Vision, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 295 Graybug Vision, Inc.: Product Benchmarking
Table 296 Kubota Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 297 Kubota Vision Inc.: Product Benchmarking
List of Figures
Figure 1 Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Segmentation
Figure 2 Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Market Trends
Figure 3 Global AMD and Other Retinal Diseases Drugs Market: SWOT Analysis
Figure 4 Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Porter’s Five Forces Analysis
Figure 5 Global AMD and Other Retinal Diseases Drugs Market: PEST Analysis
Figure 6 Global AMD and Other Disease Drugs Market Share Forecast by Indication, 2021, 2026, 2031 (%)
Figure 7 Global AMD and Other Disease Drugs Market for AMD Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 8 Global AMD and Other Disease Drugs Market for AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 9 Global AMD and Other Disease Drugs Market for AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 10 Global AMD and Other Disease Drugs Market for AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 11 Global AMD and Other Disease Drugs Market for AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 12 Global Wet AMD Segment Forecast: Revenue ($bn), AGR (%), 2020-2031
Figure 13 Global AMD Market for Wet AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 14 Global AMD Market for Wet AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 15 Global AMD Market for Wet AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 16 Global AMD Market for Wet AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 17 Global AMD Market for Dry AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 18 Global AMD Market for Dry AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 19 Global AMD Market for Dry AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 20 Global AMD Market for Dry AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 21 Global AMD Market for Geographic Atrophy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 22 Global AMD Market for Geographic Atrophy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 23 Global AMD Market for Geographic Atrophy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 24 Global AMD Market for Geographic Atrophy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 25 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 26 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 27 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 28 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 29 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 30 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 31 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 32 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 33 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 34 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 35 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 36 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 37 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 38 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 39 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 40 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 41 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 42 Global AMD and Other Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR %)
Figure 43 Global AMD and Other Disease Drugs Market Share Forecast by Product, 2021, 2026, 2031 (%)
Figure 44 Global AMD and Other Disease Drugs Market for Lucentis Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 45 Global AMD and Other Disease Drugs Market for Lucentis Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 46 Global AMD and Other Disease Drugs Market for Lucentis Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 47 Global AMD and Other Disease Drugs Market for Lucentis Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 48 Global AMD and Other Disease Drugs Market for Eylea Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 49 Global AMD and Other Disease Drugs Market for Eylea Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 50 Global AMD and Other Disease Drugs Market for Eylea Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 51 Global AMD and Other Disease Drugs Market for Eylea Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 52 Drivers and Restraints for Eylea, 2020
Figure 53 Global Avastin Segment Forecast: Revenue ($bn), AGR (%), 2020-2031
Figure 54 Global AMD and Other Disease Drugs Market for Avastin Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 55 Global AMD and Other Disease Drugs Market for Avastin Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 56 Global AMD and Other Disease Drugs Market for Avastin Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 57 Global AMD and Other Disease Drugs Market for Avastin Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 58 Drivers and Restraints for Avastin, 2020
Figure 59 Global Visudyne Segment Forecast: Revenue ($bn), AGR (%), 2020-2031
Figure 60 Global AMD and Other Disease Drugs Market for Visudyne Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 61 Global AMD and Other Disease Drugs Market for Visudyne Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 62 Global AMD and Other Disease Drugs Market for Visudyne Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 63 Global AMD and Other Disease Drugs Market for Visudyne Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 64 Global Other Drugs Segment Forecast: Revenue ($bn), AGR (%), 2020-2031
Figure 65 Global AMD and Other Disease Drugs Market for Other Drugs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 66 Global AMD and Other Disease Drugs Market for Other Drugs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 67 Global AMD and Other Disease Drugs Market for Other Drugs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 68 Global AMD and Other Disease Drugs Market for Other Drugs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 69 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR %)
Figure 70 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Share Forecast by Distribution Channel, 2021, 2026, 2031 (%)
Figure 71 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 72 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 73 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 74 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 75 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 76 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 77 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 78 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 79 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 80 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 81 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 82 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 83 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 84 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 85 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 86 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region 2021-2031 (US$ billion)
Figure 87 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Share Forecast by Region 2021, 2026, 2031 (%)
Figure 88 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 89 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 90 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 91 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 92 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 93 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 94 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 95 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 96 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 97 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR%)
Figure 98 North America Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ billion, AGR%)
Figure 99 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR%)
Figure 100 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR%)
Figure 101 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 102 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 103 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 104 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 105 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 106 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 107 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 108 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 109 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 110 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 111 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 112 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 113 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 114 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 115 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 116 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR%)
Figure 117 Europe Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ billion, AGR%)
Figure 118 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR%)
Figure 119 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR%)
Figure 120 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 121 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 122 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 123 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 124 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 125 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 126 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 127 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 128 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 129 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 130 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 131 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 132 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 133 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 134 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 135 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 136 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 137 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 138 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 139 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 140 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 141 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 142 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 143 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 144 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 145 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 146 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 147 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 148 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 149 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 150 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 151 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 152 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 153 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 154 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 155 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 156 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 157 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 158 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 159 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 160 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR%)
Figure 161 Asia Pacific Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ billion, AGR%)
Figure 162 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR%)
Figure 163 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR%)
Figure 164 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 165 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 166 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 167 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 168 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 169 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 170 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 171 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 172 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 173 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 174 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 175 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 176 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 177 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 178 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 179 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 180 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 181 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 182 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 183 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 184 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 185 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 186 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 187 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 188 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 189 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 190 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 191 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 192 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 193 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 194 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 195 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 196 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 197 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 198 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 199 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR%)
Figure 200 Latin America Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ billion, AGR%)
Figure 201 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR%)
Figure 202 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR%)
Figure 203 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 204 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 205 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 206 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 207 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 208 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 209 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 210 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 211 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 212 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 213 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 214 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 215 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 216 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 217 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 218 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 219 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 220 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 221 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 222 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 223 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 224 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 225 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 226 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 227 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 228 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR%)
Figure 229 MEA Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ billion, AGR%)
Figure 230 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR%)
Figure 231 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR%)
Figure 232 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 233 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 234 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 235 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 236 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 237 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 238 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 239 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 240 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 241 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 242 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 243 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 244 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 245 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 246 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 247 Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Company Share Analysis, 2020
Figure 248 Novatis AG: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 249 Novatis AG: Product Revenue Shares, 2019
Figure 250 Novartis AG.: Pharmaceuticals Business Unit Revenue Shares, 2019
Figure 251 Novatis AG: Regional Revenue Shares, 2019
Figure 252 F. Hoffmann-La Roche, Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 253 F. Hoffmann-La Roche, Ltd.: Product Revenue Shares, 2019
Figure 254 F. Hoffmann-La Roche, Ltd.: Pharmaceuticals Business Revenue Shares, 2019
Figure 255 F. Hoffmann-La Roche, Ltd.: Regional Revenue Shares, 2019
Figure 256 GlaxoSmithKline Pharmaceuticals Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 257 GlaxoSmithKline Pharmaceuticals Ltd.: Product Revenue Shares, 2019
Figure 258 GlaxoSmithKline Pharmaceuticals Ltd.: Pharmaceutical Segment Revenue Shares, 2019
Figure 259 GlaxoSmithKline Pharmaceuticals Ltd.: Regional Revenue Shares, 2019
Figure 260 Bayer AG: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 261 Bayer AG: Product Revenue Shares, 2019
Figure 262 Bayer AG: Regional Revenue Shares, 2019
Figure 263 Pfizer Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 264 Pfizer Inc.: Product Revenue Shares, 2019
Figure 265 Pfizer Inc.: Regional Revenue Shares, 2019
Figure 266 Regeneron Pharmaceuticals: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 267 Regeneron Pharmaceuticals: Product Revenue Shares, 2019
Figure 268 Regeneron Pharmaceuticals: Regional Revenue Shares, 2019
Figure 269 Bausch & Lomb Incorporated: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 270 Bausch & Lomb Incorporated: Product Revenue Shares, 2019
Figure 271 Bausch & Lomb Incorporated: Regional Revenue Shares, 2019
Figure 272 Santen Pharmaceuticals: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 273 Alimera Sciences: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 274 Alimera Sciences: Regional Revenue Shares, 2019
Figure 275 AbbVie Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 276 AbbVie Inc.: Product Revenue Shares, 2019
Figure 277 AbbVie Inc.: Regional Revenue Shares, 2019
Figure 278 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product 2020, 2026, & 2031 (US$ billion)
Figure 279 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region 2021-2031 (US$ billion)
1.1 Introduction to Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market
1.1.1 What are Retinal Diseases?
1.1.2 Types of Retinal Diseases
1.1.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
1.1.4 Nearly 200 Million People with AMD?
1.1.5 Over 100 Million with DR
1.1.6 First RVO Estimates Suggest Patient Population of 16 Million
1.2 Why You Should Read This Report
1.3 What This Report Delivers
1.4 Key Questions Answered By This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation & Forecast Methodology
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2 Executive Summary
3 Market Dynamics
3.1 Drivers
3.1.1 Rise in Incidence of Retinal Disorders
3.1.2 Upsurge in Geriatric Population
3.2 Restraints
3.2.1 Increasing Use of Generic Drugs
3.2.2 Lack of Awareness regarding AMD
3.2.3 Stringent FDA Regulations
3.3 Opportunities
3.3.1 Growing Demand for Cutting-edge Therapeutic Treatments for Retinal Diseases to Aid Market
3.3.2 Untapped Opportunities for the Dry-AMD Treatment
3.4 Trends
3.4.1 Mergers, Agreements, and Acquisitions By The Market Players
3.4.2 New Product Launches to Drive Market
3.5 SWOT Analysis
3.5.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
3.5.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
3.5.3 Opportunities: New Markets and R&D Synergies
3.5.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
3.6 Porter’s Five Forces Analysis
3.6.1 Bargaining Power of Supplier: Moderate
3.6.2 Bargaining Power of Buyer: Moderate
3.6.3 Competitive Rivalry: High
3.6.4 Threat of New Entrants: Moderate
3.6.5 Threat of Substitutes: Moderate
3.7 PEST Analysis
3.7.1 Political Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: The Demography and Diabetes Challenges
3.7.2 Economic Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: Off-Label Treatment and Reimbursement Issues
3.7.3 Social Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: Low Diagnosis, Low Compliance
3.7.4 Technological Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: Innovation for the Eye
4 COVID-19 Impact: Global AMD and Other Disease Drugs Market
4.1.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
4.1.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
4.1.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
4.1.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth
5 World AMD and Other Disease Drugs Market, 2020
5.1 Market to Grow Rapidly by 2031
5.2 Eylea Became Leading Drug in the Market
5.3 Regeneron is the Leading Player in the Retinal Drug Market
6 AMD and Other Disease Drugs Market by Indication Forecast, 2021-2031
6.1 AMD Segment Market Forecast, 2021-2031
6.1.1 Largest Revenue-Grossing Segment
6.1.2 Recovery Scenarios (V, U, W, L)
6.1.3 Wet AMD Segment Market Forecast, 2021-2031
6.1.3.1 Wet AMD Angiogenic Processes Offer Well-Defined Drug Targets
6.1.3.2 Wet AMD Segment Market Forecast, 2021-2031
6.1.3.3 Recovery Scenarios (V, U, W, L)
6.1.4 Dry AMD Segment Market Forecast, 2021-2031
6.1.4.1 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
6.1.4.2 Revenue Forecast for Wet AMD segment, 2020-2031
6.1.4.3 Recovery Scenarios (V, U, W, L)
6.1.5 Geographic Atrophy Segment Market Forecast, 2021-2031
6.1.5.1 Geographic Atrophy: Unmet Need to Arrest or Reverse Damage to RPE
6.1.5.2 Revenue Forecast for Geographic Atrophy segment, 2020-2031
6.1.5.3 Recovery Scenarios (V, U, W, L)
6.2 Diabetic Macular Edema Market Forecast, 2021-2031
6.2.1 Fast Growing Segment
6.2.2 Revenue Forecast for Diabetic Macular Edema segment, 2020-2031
6.2.3 Recovery Scenarios (V, U, W, L)
6.3 Diabetic Retinopathy Market Forecast, 2021-2031
6.3.1 Diabetic Retinopathy: Coming into Clinical Focus, with DME the Main Target
6.3.2 Segment to Grow in Importance as Diabetes Epidemic Continues
6.3.3 Recovery Scenarios (V, U, W, L)
6.4 Retinal Vein Occlusion Market Forecast, 2021-2031
6.4.1 Retinal Vein Occlusion Is The Second Most Common Vascular Disease Of The Retina
6.4.2 Recovery Scenarios (V, U, W, L)
6.5 Other Retinal Diseases Market Forecast, 2021-2031
6.5.1 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
6.5.2 Recovery Scenarios (V, U, W, L)
7 AMD and Other Disease Drugs Market by Product Forecast, 2021-2031
7.1 Will the Current Products Dominate the Market through 2031?
7.2 Lucentis: Second Leading Drug in the Market
7.2.1 Recovery Scenarios (V, U, W, L)
7.2.2 Shadow of Avastin Still Hangs Over Lucentis
7.2.3 Lucentis/Avastin Matters
7.2.4 Eylea: The Bigger Threat to Lucentis?
7.2.5 Extending the Label, Widening the Battleground: Lucentis Moves into DME and Beyond
7.2.6 Improving Cost and Compliance for Lucentis
7.2.7 Will Loss of Physician Goodwill Harm Lucentis' Growth?
7.3 Eylea: Holds the Throne?
7.3.1 Increasing Revenue Growth in Past: Outside the US Sale Amplified
7.3.2 Recovery Scenarios (V, U, W, L)
7.3.3 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
7.3.4 First Wave of Eylea's Expansion Finally Beginning to Break?
7.3.5 Eylea into DME and Other New Indications
7.3.6 How Far Can Eylea's Momentum Carry It?
7.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
7.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
7.4.2 Recovery Scenarios (V, U, W, L)
7.4.3 Judicial Review Averted in the UK by Price Adjustment
7.4.4 Multiple Attempts to Block Off-Label Avastin Since 2007
7.4.5 Roche and Novartis Challenge CATTs Headline Conclusions
7.4.6 Will Eylea/Zaltrap Affect Avastin's Place in the Market?
7.4.7 Will Anything Dislodge Avastin from its Central Position?
7.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
7.5.1 Visudyne Revenue Forecast, 2021-2031
7.5.2 Recovery Scenarios (V, U, W, L)
7.6 Other Drugs for Macular Degeneration and Other Retinal Diseases
7.6.1 Other Drugs Revenue Forecast, 2021-2031
7.6.2 Recovery Scenarios (V, U, W, L)
8 Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Distribution Channel Forecast, 2021-2031
8.1 Hospital Pharmacy Segment Market Forecast, 2021-2031
8.1.1 Largest Revenue Generating Segment
8.1.2 Recovery Scenarios (V, U, W, L)
8.2 Retail Pharmacy Segment Market Forecast, 2021-2031
8.2.1 Fastest Growing Segment in the Market
8.2.2 Recovery Scenarios (V, U, W, L)
8.3 Others Segment Market Forecast, 2021-2031
8.3.1 Developing Healthcare Infrastructure Is Expected To Drive The Market Growth
8.3.2 Recovery Scenarios (V, U, W, L)
9 Wet AMD Segment: Pipeline Analysis
9.1 The Leading Pipeline Candidates
9.2 Eylea® (aflibercept)
9.3 Brolucizumab (Novartis)
9.4 KSI-301
9.5 OPT-302
9.6 GB-102
9.7 Combination of Drugs for the Treatment of AMD and Other Retinal Diseases
9.7.1 Anti-VEGF and Cosopt (Dorzolamide-timolol) Drugs
9.7.2 REGN 910-3 and RG7716
9.7.3 Anti-VEGF and OPT-302 Drugs
9.7.4 Others Combination Therapy Developments
10 Pipeline for Dry AMD Segment
10.1 Apl-2
10.2 Zimura
10.3 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
10.4 Neuroprotection: One of Modern Medicine's Holy Grails
10.5 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
10.6 Elamipretide
10.7 Subthreshold Nanosecond Laser
10.8 Lampalizumab
11 Pipeline for Diabetic Retinopathy Segment
11.1 Steroids in Development for DR
11.2 APX3330
12 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
12.1 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Region Forecast 2021-2031
12.2 Recovery Scenarios (V, U, W, L)
12.3 Epidemiology of Global Age-Related Macular Degeneration in Nine Major Pharmaceutical Markets
13 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
13.1 North America is The Largest Revenue Grossing Region in the Global Market
13.2 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
13.3 Recovery Scenarios (V, U, W, L)
13.4 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
13.5 North America Macular Degeneration (AMD) Drugs Market Forecast by Type
13.6 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
13.7 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
13.8 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
13.8.1 Rise In The Number Of Drug Approvals
13.8.2 Presence of Highly Developed Healthcare Infrastructure
13.8.3 Recovery Scenarios (V, U, W, L): U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
13.9 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
13.9.1 Anticipated To Witness The Fastest Growth In The North America Region
13.9.2 Benefits Of Manufacturing And R&D Operations In Canada
13.9.3 Recovery Scenarios (V, U, W, L): Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
14.1 Second Largest Market in the Global Market
14.2 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
14.3 Recovery Scenarios (V, U, W, L)
14.4 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
14.5 Europe Macular Degeneration (AMD) Drugs Market Forecast by Type
14.6 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
14.7 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
14.8 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.8.1 Growing Geriatric Population In This Region Is Expected To Boost The Regional Market Growth
14.8.2 One Of The Oldest Universal Health Systems Within Europe
14.8.3 Recovery Scenarios (V, U, W, L): Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.9 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.9.1 Presence Of Well-Developed R&D Infrastructure
14.9.2 Increasing Prevalence Of Retinal Diseases In This Region
14.9.3 Recovery Scenarios (V, U, W, L): UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.10 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.10.1 Growing Demand For Affordable Healthcare Services
14.10.2 Growing Demand For Innovative Medicine And Pharmaceutical
14.10.3 Recovery Scenarios (V, U, W, L): France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.11 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.11.1 Pharmaceutical Manufacturing Hub
14.11.2 Growing Demand For Advanced Therapies For The Treatment Of Retinal Diseases
14.11.3 Recovery Scenarios (V, U, W, L): Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.12 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.12.1 Spanish Economy Is Growing Strong
14.12.2 Demand For Drugs Is Influenced By The Growth Of The Pharmaceutical Industry
14.12.3 Recovery Scenarios (V, U, W, L): Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.13 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.13.1 Unmet Pharmaceutical Needs
14.13.2 Government Support For Development of the Healthcare Infrastructure
14.13.3 Recovery Scenarios (V, U, W, L): Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.14 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.14.1 Increasing Prevalence Of Retinal Diseases
14.14.2 Recovery Scenarios (V, U, W, L): Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
15.1 Asia Pacific is the Fastest Growing Market
15.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
15.3 Recovery Scenarios (V, U, W, L)
15.4 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
15.5 Asia Pacific Macular Degeneration (AMD) Drugs Market Forecast by Type
15.6 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
15.7 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
15.8 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.8.1 Japan Accounted For The Largest Market Share In The Asia Pacific Region
15.8.2 Japan Spent A High Amount On Healthcare
15.8.3 Recovery Scenarios (V, U, W, L): Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.9 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.9.1 Presence Of Large Geriatric Population
15.9.2 Increasing Healthcare Spending In China
15.9.3 Recovery Scenarios (V, U, W, L): China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.10 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.10.1 Developing Healthcare Infrastructure
15.10.2 Increasing Prevalence Of Retinal Diseases
15.10.3 Recovery Scenarios (V, U, W, L): India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.11 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.11.1 Government Programs To Expand Access To Quality Eye Care Facilities
15.11.2 Well Established Healthcare Infrastructure
15.11.3 Recovery Scenarios (V, U, W, L): Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.12 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.12.1 Growing Healthcare Awareness Among People
15.12.2 Increasing Prevalence Of Retinal Diseases
15.12.3 Recovery Scenarios (V, U, W, L): South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.13 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.13.1 Rising Disposable Income
15.13.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
16.1 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market
16.2 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
16.3 Recovery Scenarios (V, U, W, L)
16.4 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
16.5 Latin America Macular Degeneration (AMD) Drugs Market Forecast by Type
16.6 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
16.7 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
16.8 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.8.1 Fastest Growing Economies in Latin America
16.8.2 Government Incentives to Keep Manufacturing Local
16.8.3 Recovery Scenarios (V, U, W, L): Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.9 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.9.1 Lower Manufacturing Costs Than In The US
16.9.2 R&D And Drug Approval Process in Mexico Has Several Advantages
16.9.3 Recovery Scenarios (V, U, W, L): Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.10 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.10.1 Boom in Pharmaceutical Industry
16.10.2 Adoption Of AMD And Other Retinal Diseases Drugs For The Treatment Of Retinal Diseases
16.10.3 Recovery Scenarios (V, U, W, L): Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.11 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.11.1 Developing Healthcare Infrastructure
16.11.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
17.1 Rising Prevalence of Chronic Retinal Diseases
17.2 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
17.3 Recovery Scenarios (V, U, W, L)
17.4 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
17.5 MEA Macular Degeneration (AMD) Drugs Market Forecast by Type
17.6 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
17.7 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
17.8 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.8.1 Increasing Focus Of Pharmaceutical & Pharmaceutical Companies In This Region
17.8.2 Supportive Government Initiatives
17.8.3 Recovery Scenarios (V, U, W, L): South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.9 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.9.1 Presence Of Huge Growth Opportunities
17.9.2 Rising Prevalence Of The Diseases
17.9.3 Recovery Scenarios (V, U, W, L): Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.10 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.10.1 Strong Presence Of Leading Companies
17.10.2 Growing Prevalence of Retinal Diseases
17.10.3 Recovery Scenarios (V, U, W, L): Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
18 Company Profiles
18.1 Company Share Analysis
18.2 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Recent Developments, 2017-2020
18.3 Novartis AG
18.3.1 Company Snapshot
18.3.2 Company Overview
18.3.3 Financial Analysis
18.3.3.1 Net Revenue, 2015-2019
18.3.3.2 Product Revenue Shares, 2019
18.3.3.3 Novartis Pharmaceuticals Business Unit Revenue Shares, 2019
18.3.3.4 Regional Revenue Shares, 2019
18.3.4 Product Benchmarking
18.3.5 Recent Developments, 2017-2020
18.4 F. Hoffmann-La Roche, Ltd.
18.4.1 Company Snapshot
18.4.2 Company Overview
18.4.3 Financial Analysis
18.4.3.1 Net Revenue, 2015-2019
18.4.3.2 Product Revenue Shares, 2019
18.4.3.3 Pharmaceuticals Business Revenue Shares, 2019
18.4.3.4 Regional Revenue Shares, 2019
18.4.4 Product Benchmarking
18.4.5 Recent Developments, 2017-2020
18.5 GlaxoSmithKline Pharmaceuticals Ltd.
18.5.1 Company Snapshot
18.5.2 Company Overview
18.5.3 Financial Analysis
18.5.3.1 Net Revenue, 2015-2019
18.5.3.2 Product Revenue Shares, 2019
18.5.3.3 Pharmaceuticals Segment Revenue Shares, 2019
18.5.3.4 Regional Revenue Shares, 2019
18.5.4 Product Benchmarking
18.5.5 Recent Developments, 2017-2020
18.6 Bayer AG
18.6.1 Company Snapshot
18.6.2 Company Overview
18.6.3 Financial Analysis
18.6.3.1 Net Revenue, 2015-2019
18.6.3.2 Product Revenue Shares, 2019
18.6.3.3 Regional Revenue Shares, 2019
18.6.4 Product Benchmarking
18.6.5 Recent Developments, 2017-2020
18.7 Pfizer Inc.
18.7.1 Company Snapshot
18.7.2 Company Overview
18.7.3 Financial Analysis
18.7.3.1 Net Revenue, 2015-2019
18.7.3.2 Product Revenue Shares, 2019
18.7.3.3 Regional Revenue Shares, 2019
18.7.4 Product Benchmarking
18.7.5 Recent Developments, 2017-2020
18.8 Regeneron Pharmaceuticals
18.8.1 Company Snapshot
18.8.2 Company Overview
18.8.3 Financial Analysis
18.8.3.1 Net Revenue, 2015-2019
18.8.3.2 Product Revenue Shares, 2019
18.8.3.3 Regional Revenue Shares, 2019
18.8.4 Product Benchmarking
18.8.5 Recent Developments, 2017-2020
18.9 Bausch & Lomb Incorporated
18.9.1 Company Snapshot
18.9.2 Company Overview
18.9.3 Financial Analysis
18.9.3.1 Net Revenue, 2015-2019
18.9.3.2 Product Revenue Shares, 2019
18.9.3.3 Regional Revenue Shares, 2019
18.9.4 Product Benchmarking
18.9.5 Recent Developments, 2017-2020
18.10 Apellis Pharmaceuticals
18.10.1 Company Snapshot
18.10.2 Company Overview
18.10.3 Product Benchmarking
18.10.4 Recent Developments, 2017-2020
18.11 Santen Pharmaceuticals
18.11.1 Company Snapshot
18.11.2 Company Overview
18.11.3 Financial Analysis
18.11.3.1 Net Revenue, 2015-2019
18.11.4 Product Benchmarking
18.11.5 Recent Developments, 2017-2020
18.12 Alimera Sciences
18.12.1 Company Snapshot
18.12.2 Company Overview
18.12.3 Financial Analysis
18.12.3.1 Net Revenue, 2015-2019
18.12.3.2 Regional Revenue Shares, 2019
18.12.4 Product Benchmarking
18.12.5 Recent Developments, 2017-2020
18.13 AbbVie Inc.
18.13.1 Company Snapshot
18.13.2 Company Overview
18.13.3 Financial Analysis
18.13.3.1 Net Revenue, 2015-2019
18.13.3.2 Product Revenue Shares, 2019
18.13.3.3 Regional Revenue Shares, 2019
18.13.4 Product Benchmarking
18.13.5 Recent Developments, 2017-2020
18.14 IVERIC bio, Inc. (Formerly Ophthotech)
18.14.1 Company Snapshot
18.14.2 Company Overview
18.14.3 Product Benchmarking
18.15 Graybug Vision, Inc.
18.15.1 Company Snapshot
18.15.2 Company Overview
18.15.3 Product Benchmarking
18.16 Kubota Vision Inc.
18.16.1 Company Snapshot
18.16.2 Company Overview
18.16.3 Product Benchmarking
19 Conclusion and Recommendations
19.1 Increasing Prevalence of Retinal Disorders and Diabetes is a Major Factor Driving The Market Growth
19.2 Negative Impact of the COVID-19 Pandemic on the Market
19.3 Eylea Dominated the AMD and Other Retinal Diseases Market
19.4 Market Opportunities in the Emerging Economies
List of Tables
Table 1 Global AMD and other retinal disease drugs market, 2020 & 2031 (US$ bn, CAGR %)
Table 2 World AMD and Other Retinal Diseases Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "V" Shaped Recovery
Table 3 World AMD and Other Retinal Diseases Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "U" Shaped Recovery
Table 4 World AMD and Other Retinal Diseases Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "W" Shaped Recovery
Table 5 World AMD and Other Retinal Diseases Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031: "L" Shaped Recovery
Table 6 World AMD and Other Retinal Diseases Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2031
Table 7 Market Breakdown by Product: Revenue ($Bn), Market Share (%), 2020 (Pre COVID)
Table 8 Global AMD and Other Disease Drugs Market Forecast by Indication: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 9 Global Retinal Diseases Market Forecasts by Indication: Revenue: ($bn), Market Share (%) for 2021, 2026 and 2031
Table 10 Global AMD and Other Disease Drugs Market for AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 11 Global AMD and Other Disease Drugs Market for AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 12 Global AMD and Other Disease Drugs Market for AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 13 Global AMD and Other Disease Drugs Market for AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 14 Global AMD and Other Disease Drugs Market for AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 15 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2020
Table 16 Global Wet AMD Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 17 Global AMD Market for Wet AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 18 Global AMD Market for Wet AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 19 Global AMD Market for Wet AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 20 Global AMD Market for Wet AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 21 Global AMD Market for Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 22 Global AMD Market for Dry AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 23 Global AMD Market for Dry AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 24 Global AMD Market for Dry AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 25 Global AMD Market for Dry AMD Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 26 Global Geographic Atrophy (GA) Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 27 Global AMD Market for Geographic Atrophy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 28 Global AMD Market for Geographic Atrophy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 29 Global AMD Market for Geographic Atrophy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 30 Global AMD Market for Geographic Atrophy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 31 Global Diabetic Macular Edema Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 32 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 33 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 34 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 35 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 36 Global Diabetic Retinopathy Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 37 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 38 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 39 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 40 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 41 Global Retinal Vein Occlusion Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 42 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 43 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 44 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 45 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 46 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 47 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 48 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 49 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 50 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 51 Global Retinal Diseases Market Forecast by Drugs: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 52 Global Retinal Diseases Market Forecasts by Product: Revenue: ($bn), Market Share (%) for 2021, 2026 and 2031
Table 53 Global Lucentis Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 54 Global AMD and Other Disease Drugs Market for Lucentis Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 55 Global AMD and Other Disease Drugs Market for Lucentis Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 56 Global AMD and Other Disease Drugs Market for Lucentis Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 57 Global AMD and Other Disease Drugs Market for Lucentis Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 58 Lucentis, Eylea and Avastin: Comparison
Table 59 Global Eylea Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 60 Global AMD and Other Disease Drugs Market for Eylea Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 61 Global AMD and Other Disease Drugs Market for Eylea Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 62 Global AMD and Other Disease Drugs Market for Eylea Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 63 Global AMD and Other Disease Drugs Market for Eylea Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 64 Global Avastin Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 65 Global AMD and Other Disease Drugs Market for Avastin Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 66 Global AMD and Other Disease Drugs Market for Avastin Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 67 Global AMD and Other Disease Drugs Market for Avastin Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 68 Global AMD and Other Disease Drugs Market for Avastin Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 69 Global Visudyne Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 70 Global AMD and Other Disease Drugs Market for Visudyne Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 71 Global AMD and Other Disease Drugs Market for Visudyne Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 72 Global AMD and Other Disease Drugs Market for Visudyne Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 73 Global AMD and Other Disease Drugs Market for Visudyne Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 74 Global Other Drugs Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2031
Table 75 Global AMD and Other Disease Drugs Market for Other Drugs Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 76 Global AMD and Other Disease Drugs Market for Other Drugs Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 77 Global AMD and Other Disease Drugs Market for Other Drugs Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 78 Global AMD and Other Disease Drugs Market for Other Drugs Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 79 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 80 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 81 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 82 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 83 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 84 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 85 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 86 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 87 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 88 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 89 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 90 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 91 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 92 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 93 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 94 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 95 Selected R&D Pipeline for wAMD, 2019
Table 96 Selected R&D Pipeline for Dry AMD, 2019
Table 97 Selected R&D Pipeline for DR, 2019
Table 98 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 99 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 100 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 101 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 102 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 103 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 104 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 105 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 106 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 107 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 108 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 109 North America Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 110 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 111 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 112 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 113 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 114 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 115 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 116 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 117 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 118 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 119 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 120 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 121 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 122 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 123 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 124 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 125 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 126 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 127 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 128 Europe Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 129 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 130 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 131 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 132 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 133 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 134 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 135 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 136 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 137 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 138 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 139 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 140 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 141 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 142 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 143 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 144 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 145 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 146 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 147 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 148 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 149 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 150 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 151 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 152 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 153 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 154 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 155 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 156 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 157 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 158 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 159 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 160 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 161 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 162 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 163 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 164 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 165 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 166 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 167 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 168 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 169 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 170 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 171 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 172 Asia Pacific Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 173 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 174 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 175 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 176 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 177 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 178 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 179 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 180 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 181 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 182 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 183 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 184 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 185 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 186 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 187 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 188 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 189 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 190 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 191 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 192 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 193 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 194 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 195 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 196 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 197 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 198 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 199 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 200 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 201 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 202 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 203 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 204 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 205 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 206 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 207 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 208 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 209 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 210 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 211 Latin America Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 212 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 213 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 214 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 215 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 216 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 217 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 218 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 219 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 220 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 221 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 222 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 223 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 224 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 225 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 226 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 227 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 228 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 229 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 230 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 231 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 232 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 233 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 234 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 235 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 236 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 237 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 238 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 239 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 240 MEA Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 241 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 242 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 243 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 244 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 245 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 246 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 247 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 248 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 249 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 250 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 251 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 252 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 253 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%)
Table 254 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "V" Shaped Recovery
Table 255 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "U" Shaped Recovery
Table 256 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "W" Shaped Recovery
Table 257 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ bn, AGR%, CAGR%): "L" Shaped Recovery
Table 258 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Recent Developments, 2017-2020
Table 259 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 260 Novatis AG: Product Benchmarking
Table 261 Novatis AG: Recent Developments, 2017-2020
Table 262 F. Hoffmann-La Roche, Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 263 F. Hoffmann-La Roche, Ltd.: Product Benchmarking
Table 264 F. Hoffmann-La Roche, Ltd.: Recent Developments, 2017-2020
Table 265 GlaxoSmithKline Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 266 GlaxoSmithKline Pharmaceuticals Ltd.: Product Benchmarking
Table 267 GlaxoSmithKline Pharmaceuticals Ltd.: Recent Developments, 2017-2020
Table 268 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 269 Bayer AG: Product Benchmarking
Table 270 Bayer AG: Recent Developments, 2017-2020
Table 271 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 272 Pfizer Inc.: Product Benchmarking
Table 273 Pfizer Inc.: Recent Developments, 2017-2020
Table 274 Regeneron Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 275 Regeneron Pharmaceuticals: Product Benchmarking
Table 276 Regeneron Pharmaceuticals: Recent Developments, 2017-2020
Table 277 Bausch & Lomb Incorporated: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 278 Bausch & Lomb Incorporated: Product Benchmarking
Table 279 Bausch & Lomb Incorporated: Recent Developments, 2017-2020
Table 280 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 281 Apellis Pharmaceuticals: Product Benchmarking
Table 282 Apellis Pharmaceuticals: Recent Developments, 2017-2020
Table 283 Santen Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 284 Santen Pharmaceuticals: Product Benchmarking
Table 285 Santen Pharmaceuticals: Recent Developments, 2017-2020
Table 286 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 287 Alimera Sciences: Product Benchmarking
Table 288 Alimera Sciences: Recent Developments, 2017-2020
Table 289 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 290 AbbVie Inc.: Product Benchmarking
Table 291 AbbVie Inc.: Recent Developments, 2017-2020
Table 292 IVERIC bio, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 293 IVERIC bio, Inc.: Product Benchmarking
Table 294 Graybug Vision, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 295 Graybug Vision, Inc.: Product Benchmarking
Table 296 Kubota Vision Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 297 Kubota Vision Inc.: Product Benchmarking
List of Figures
Figure 1 Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Segmentation
Figure 2 Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Market Trends
Figure 3 Global AMD and Other Retinal Diseases Drugs Market: SWOT Analysis
Figure 4 Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Porter’s Five Forces Analysis
Figure 5 Global AMD and Other Retinal Diseases Drugs Market: PEST Analysis
Figure 6 Global AMD and Other Disease Drugs Market Share Forecast by Indication, 2021, 2026, 2031 (%)
Figure 7 Global AMD and Other Disease Drugs Market for AMD Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 8 Global AMD and Other Disease Drugs Market for AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 9 Global AMD and Other Disease Drugs Market for AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 10 Global AMD and Other Disease Drugs Market for AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 11 Global AMD and Other Disease Drugs Market for AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 12 Global Wet AMD Segment Forecast: Revenue ($bn), AGR (%), 2020-2031
Figure 13 Global AMD Market for Wet AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 14 Global AMD Market for Wet AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 15 Global AMD Market for Wet AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 16 Global AMD Market for Wet AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 17 Global AMD Market for Dry AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 18 Global AMD Market for Dry AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 19 Global AMD Market for Dry AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 20 Global AMD Market for Dry AMD Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 21 Global AMD Market for Geographic Atrophy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 22 Global AMD Market for Geographic Atrophy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 23 Global AMD Market for Geographic Atrophy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 24 Global AMD Market for Geographic Atrophy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 25 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 26 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 27 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 28 Global AMD and Other Disease Drugs Market for Diabetic Macular Edema Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 29 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 30 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 31 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 32 Global AMD and Other Disease Drugs Market for Diabetic Retinopathy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 33 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 34 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 35 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 36 Global AMD and Other Disease Drugs Market for Retinal Vein Occlusion Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 37 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 38 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 39 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 40 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 41 Global AMD and Other Disease Drugs Market for Other Retinal Diseases Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 42 Global AMD and Other Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR %)
Figure 43 Global AMD and Other Disease Drugs Market Share Forecast by Product, 2021, 2026, 2031 (%)
Figure 44 Global AMD and Other Disease Drugs Market for Lucentis Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 45 Global AMD and Other Disease Drugs Market for Lucentis Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 46 Global AMD and Other Disease Drugs Market for Lucentis Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 47 Global AMD and Other Disease Drugs Market for Lucentis Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 48 Global AMD and Other Disease Drugs Market for Eylea Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 49 Global AMD and Other Disease Drugs Market for Eylea Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 50 Global AMD and Other Disease Drugs Market for Eylea Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 51 Global AMD and Other Disease Drugs Market for Eylea Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 52 Drivers and Restraints for Eylea, 2020
Figure 53 Global Avastin Segment Forecast: Revenue ($bn), AGR (%), 2020-2031
Figure 54 Global AMD and Other Disease Drugs Market for Avastin Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 55 Global AMD and Other Disease Drugs Market for Avastin Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 56 Global AMD and Other Disease Drugs Market for Avastin Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 57 Global AMD and Other Disease Drugs Market for Avastin Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 58 Drivers and Restraints for Avastin, 2020
Figure 59 Global Visudyne Segment Forecast: Revenue ($bn), AGR (%), 2020-2031
Figure 60 Global AMD and Other Disease Drugs Market for Visudyne Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 61 Global AMD and Other Disease Drugs Market for Visudyne Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 62 Global AMD and Other Disease Drugs Market for Visudyne Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 63 Global AMD and Other Disease Drugs Market for Visudyne Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 64 Global Other Drugs Segment Forecast: Revenue ($bn), AGR (%), 2020-2031
Figure 65 Global AMD and Other Disease Drugs Market for Other Drugs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 66 Global AMD and Other Disease Drugs Market for Other Drugs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 67 Global AMD and Other Disease Drugs Market for Other Drugs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 68 Global AMD and Other Disease Drugs Market for Other Drugs Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 69 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR %)
Figure 70 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Share Forecast by Distribution Channel, 2021, 2026, 2031 (%)
Figure 71 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 72 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 73 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 74 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 75 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Hospital Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 76 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 77 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 78 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 79 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 80 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Retail Pharmacy Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 81 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment: Revenue Forecast 2021-2031 (US$ billion, AGR%)
Figure 82 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 83 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 84 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 85 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market for Others Segment, Revenue Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 86 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region 2021-2031 (US$ billion)
Figure 87 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Share Forecast by Region 2021, 2026, 2031 (%)
Figure 88 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 89 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 90 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 91 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 92 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 93 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 94 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 95 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 96 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 97 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR%)
Figure 98 North America Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ billion, AGR%)
Figure 99 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR%)
Figure 100 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR%)
Figure 101 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 102 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 103 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 104 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 105 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 106 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 107 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 108 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 109 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 110 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 111 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 112 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 113 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 114 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 115 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 116 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR%)
Figure 117 Europe Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ billion, AGR%)
Figure 118 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR%)
Figure 119 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR%)
Figure 120 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 121 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 122 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 123 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 124 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 125 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 126 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 127 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 128 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 129 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 130 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 131 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 132 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 133 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 134 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 135 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 136 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 137 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 138 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 139 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 140 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 141 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 142 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 143 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 144 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 145 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 146 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 147 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 148 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 149 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 150 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 151 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 152 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 153 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 154 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 155 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 156 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 157 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 158 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 159 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 160 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR%)
Figure 161 Asia Pacific Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ billion, AGR%)
Figure 162 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR%)
Figure 163 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR%)
Figure 164 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 165 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 166 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 167 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 168 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 169 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 170 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 171 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 172 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 173 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 174 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 175 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 176 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 177 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 178 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 179 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 180 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 181 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 182 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 183 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 184 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 185 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 186 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 187 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 188 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 189 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 190 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 191 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 192 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 193 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 194 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 195 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 196 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 197 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 198 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 199 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR%)
Figure 200 Latin America Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ billion, AGR%)
Figure 201 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR%)
Figure 202 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR%)
Figure 203 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 204 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 205 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 206 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 207 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 208 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 209 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 210 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 211 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 212 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 213 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 214 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 215 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 216 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 217 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 218 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 219 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 220 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 221 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 222 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 223 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Country 2021-2031 (US$ billion)
Figure 224 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 225 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 226 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 227 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 228 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication, 2021-2031 (US$ billion, AGR%)
Figure 229 MEA Macular Degeneration (AMD) Drugs Market Forecast by Type, 2021-2031 (US$ billion, AGR%)
Figure 230 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product, 2021-2031 (US$ billion, AGR%)
Figure 231 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel, 2021-2031 (US$ billion, AGR%)
Figure 232 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 233 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 234 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 235 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 236 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 237 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 238 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 239 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 240 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 241 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 242 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR %)
Figure 243 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “V” Shaped Recovery
Figure 244 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “U” Shaped Recovery
Figure 245 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “W” Shaped Recovery
Figure 246 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031 (US$ billion, AGR%): “L” Shaped Recovery
Figure 247 Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market: Company Share Analysis, 2020
Figure 248 Novatis AG: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 249 Novatis AG: Product Revenue Shares, 2019
Figure 250 Novartis AG.: Pharmaceuticals Business Unit Revenue Shares, 2019
Figure 251 Novatis AG: Regional Revenue Shares, 2019
Figure 252 F. Hoffmann-La Roche, Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 253 F. Hoffmann-La Roche, Ltd.: Product Revenue Shares, 2019
Figure 254 F. Hoffmann-La Roche, Ltd.: Pharmaceuticals Business Revenue Shares, 2019
Figure 255 F. Hoffmann-La Roche, Ltd.: Regional Revenue Shares, 2019
Figure 256 GlaxoSmithKline Pharmaceuticals Ltd.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 257 GlaxoSmithKline Pharmaceuticals Ltd.: Product Revenue Shares, 2019
Figure 258 GlaxoSmithKline Pharmaceuticals Ltd.: Pharmaceutical Segment Revenue Shares, 2019
Figure 259 GlaxoSmithKline Pharmaceuticals Ltd.: Regional Revenue Shares, 2019
Figure 260 Bayer AG: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 261 Bayer AG: Product Revenue Shares, 2019
Figure 262 Bayer AG: Regional Revenue Shares, 2019
Figure 263 Pfizer Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 264 Pfizer Inc.: Product Revenue Shares, 2019
Figure 265 Pfizer Inc.: Regional Revenue Shares, 2019
Figure 266 Regeneron Pharmaceuticals: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 267 Regeneron Pharmaceuticals: Product Revenue Shares, 2019
Figure 268 Regeneron Pharmaceuticals: Regional Revenue Shares, 2019
Figure 269 Bausch & Lomb Incorporated: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 270 Bausch & Lomb Incorporated: Product Revenue Shares, 2019
Figure 271 Bausch & Lomb Incorporated: Regional Revenue Shares, 2019
Figure 272 Santen Pharmaceuticals: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 273 Alimera Sciences: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 274 Alimera Sciences: Regional Revenue Shares, 2019
Figure 275 AbbVie Inc.: Net Revenue, 2015-2019 (US$ billion, AGR%)
Figure 276 AbbVie Inc.: Product Revenue Shares, 2019
Figure 277 AbbVie Inc.: Regional Revenue Shares, 2019
Figure 278 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product 2020, 2026, & 2031 (US$ billion)
Figure 279 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Region 2021-2031 (US$ billion)
Companies Profiled in the Report:
AbbVie Inc.
Alimera Sciences
Apellis Pharmaceuticals
Bausch & Lomb Incorporated
Bayer AG
F. Hoffmann-La Roche, Ltd.
GlaxoSmithKline Pharmaceuticals Ltd.
Graybug Vision, Inc.
IVERIC bio, Inc. (Formerly Ophthotech)
Kubota Vision Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals
Santen Pharmaceuticals
List of Companies Mentioned in the Report:
ACT
Acucela
Advanced Cell Technology (now Ocata Therapeutics)
Aerie Pharmaceuticals, Inc.
Alcon
Allegro Ophthalmics, LLC
Allergan
Avalanche Biotechnologies
Biogen
Biovail Corporation
Bristol-Myers Squib
Chengdu Kanghong Biotech
CoMentis
Eli Lilly's
Ellex
Eyetech
ForSight VISION4
iCo Therapeutics
Icon Bioscience
Icon Bioscience
Iveric bio
IVERIC bio, Inc.
Kodiak Sciences
LumiThera
MacuCLEAR
Mesoblast
Molecular Partners
Morgan Stanley
Neurotech
Ocuphire Pharma
Ocuphire Pharma, Inc.
OHR Pharmaceutical
Opthea Limited
Ora Bio
Orchard Therapeutics
Orphan Biovitrum AB
Othera Pharmaceuticals
Oxford BioMedica
Oxigene
PanOptica
Phoenix
ReVision Therapeutics
Samsung Bioepis
SARcode Bioscience
Stada Arzneimittel
StemCells
Stemedica Cell Technologies
ThromboGenics
Tucson
UCB's
Valeant Pharmaceuticals
VisionCare Ophthalmic Technologies
Visudyne
Vitreoretinal Technologies
Xbrane
Xcovery Vision
List of Organizations Mentioned in the Report:
American Academy of Ophthalmology (AAO)
American Society of Retina Specialists (ASRS)
Associated Retina Consultants Phoenix, U.S.A
Barnet Dulaney Perkins Eye Center Phoenix, U.S.A
Bright Focus Foundation, U.S.
Canada's Common Drug Review
Centers for Disease Control and Prevention (CDC)
Clinical Research Network
Cochrane Collaboration
European Commission (EC)
European Medicine Agency (EMA)
Eye Research Institute, Singapore
FDA’s Centre for Drug Evaluation and Research
Food and Drug Administration (FDA)
Foundation Fighting Blindness
General Medical Council (GMC), UK
Germany's Institut fur Qualitat and Wirtschaftlichkeit im Gesundheitswesen (IQWiG; Institute for Quality and Efficiency in Healthcare)
Health Canada
International Diabetes Federation
Italian Competition Authority (ICA)
Japanese Ministry of Health, Labour and Welfare
Macula and Retina Institute Glendale, Retina Consultants of San Diego Poway, Colorado Retina Associates etc
Mental Health America
National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine
National Eye Institute
National Health Service (NHS), Scotland
National Health Service (NHS), UK
National Institute of Health (NIH)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Retina Vitreous Associates Medical Group. West Coast Retina Medical Group. Inc, etc
Retinal Consultants of Arizona LTD. Retina-Vitreous Associates Medical Group, etc
Retinal Research Institute, U.S.A
The National Institute for Health and Care Excellence (NICE), UK
University College London, UCL
World Health Organization (WHO)
AbbVie Inc.
Alimera Sciences
Apellis Pharmaceuticals
Bausch & Lomb Incorporated
Bayer AG
F. Hoffmann-La Roche, Ltd.
GlaxoSmithKline Pharmaceuticals Ltd.
Graybug Vision, Inc.
IVERIC bio, Inc. (Formerly Ophthotech)
Kubota Vision Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals
Santen Pharmaceuticals
List of Companies Mentioned in the Report:
ACT
Acucela
Advanced Cell Technology (now Ocata Therapeutics)
Aerie Pharmaceuticals, Inc.
Alcon
Allegro Ophthalmics, LLC
Allergan
Avalanche Biotechnologies
Biogen
Biovail Corporation
Bristol-Myers Squib
Chengdu Kanghong Biotech
CoMentis
Eli Lilly's
Ellex
Eyetech
ForSight VISION4
iCo Therapeutics
Icon Bioscience
Icon Bioscience
Iveric bio
IVERIC bio, Inc.
Kodiak Sciences
LumiThera
MacuCLEAR
Mesoblast
Molecular Partners
Morgan Stanley
Neurotech
Ocuphire Pharma
Ocuphire Pharma, Inc.
OHR Pharmaceutical
Opthea Limited
Ora Bio
Orchard Therapeutics
Orphan Biovitrum AB
Othera Pharmaceuticals
Oxford BioMedica
Oxigene
PanOptica
Phoenix
ReVision Therapeutics
Samsung Bioepis
SARcode Bioscience
Stada Arzneimittel
StemCells
Stemedica Cell Technologies
ThromboGenics
Tucson
UCB's
Valeant Pharmaceuticals
VisionCare Ophthalmic Technologies
Visudyne
Vitreoretinal Technologies
Xbrane
Xcovery Vision
List of Organizations Mentioned in the Report:
American Academy of Ophthalmology (AAO)
American Society of Retina Specialists (ASRS)
Associated Retina Consultants Phoenix, U.S.A
Barnet Dulaney Perkins Eye Center Phoenix, U.S.A
Bright Focus Foundation, U.S.
Canada's Common Drug Review
Centers for Disease Control and Prevention (CDC)
Clinical Research Network
Cochrane Collaboration
European Commission (EC)
European Medicine Agency (EMA)
Eye Research Institute, Singapore
FDA’s Centre for Drug Evaluation and Research
Food and Drug Administration (FDA)
Foundation Fighting Blindness
General Medical Council (GMC), UK
Germany's Institut fur Qualitat and Wirtschaftlichkeit im Gesundheitswesen (IQWiG; Institute for Quality and Efficiency in Healthcare)
Health Canada
International Diabetes Federation
Italian Competition Authority (ICA)
Japanese Ministry of Health, Labour and Welfare
Macula and Retina Institute Glendale, Retina Consultants of San Diego Poway, Colorado Retina Associates etc
Mental Health America
National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine
National Eye Institute
National Health Service (NHS), Scotland
National Health Service (NHS), UK
National Institute of Health (NIH)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Retina Vitreous Associates Medical Group. West Coast Retina Medical Group. Inc, etc
Retinal Consultants of Arizona LTD. Retina-Vitreous Associates Medical Group, etc
Retinal Research Institute, U.S.A
The National Institute for Health and Care Excellence (NICE), UK
University College London, UCL
World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031Related reports
-
Global Ophthalmic Devices Market 2020-2030
The global ophthalmic devices market is expected to grow at a CAGR of 4.9% in the first half of the...
Full DetailsPublished: 12 March 2020 -
Ophthalmic Devices Market Report 2022-2032
The number of people who are blind or have poor vision is expected to rise considerably in the coming years....Full DetailsPublished: 19 April 2022 -
Ophthalmic Drugs Market Report to 2030
The global market for ophthalmic drugs is increasing yearly. Your competitors in the ophthalmic drugs market are benefiting from key...Full DetailsPublished: 26 November 2020 -
Global Ophthalmic Knives Market Report 2019-2029
Ophthalmic Knives are used during the surgery of the patients suffering from ophthalmic diseases such as cataracts, keratosis and others....
Full DetailsPublished: 01 January 1970 -
Ophthalmic Drugs Market Report 2023-2033
Ophthalmic drugs market was valued at US$29.07 billion in 2022 and is projected to grow at a CAGR of 6.39%...Full DetailsPublished: 13 September 2022 -
Ophthalmic Ultrasound Systems Market Report 2020-2030
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases,...
Full DetailsPublished: 07 September 2020 -
Pharma Leader Series: Top 30 Ophthalmic Drug Manufacturers 2019-2029
The global ophthalmic drugs market was valued at $25bn in 2018. The market was dominated by the Retinal Disorder drug...Full DetailsPublished: 15 August 2019 -
Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031
The global market for ophthalmic drugs is increasing yearly. Your competitors in the ophthalmic drugs market are benefiting from key...Full DetailsPublished: 04 March 2021 -
Global Optometry/Eye Exam Equipment Market 2019-2029
Optometry/Eye examination equipment are required for the diagnosis, examination of an eye and treatment of various eye diseases such as...
Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
